Class III β-tubulin overexpression within the tumor microenvironment is a prognostic biomarker for poor overall survival in ovarian cancer patients treated with neoadjuvant carboplatin/paclitaxel

TLR2 enhances ovarian cancer stem cell self-renewal and promotes tumor repair and recurrence

(2013) Ilana Chefetz et al.   CELL CYCLE

Gender Influences the Class III and V  -Tubulin Ability to Predict Poor Outcome in Colorectal Cancer

(2012) M. Mariani et al.   CLINICAL CANCER RESEARCH

Uterine papillary serous cancer: A review of the literature

(2012) Marcela G. del Carmen et al.   GYNECOLOGIC ONCOLOGY

Neoadjuvant chemotherapy (NACT) is an effective way of managing elderly women with advanced stage ovarian cancer (FIGO Stage IIIC and IV)

(2012) Michelle A. Glasgow et al.   JOURNAL OF SURGICAL ONCOLOGY

Phase II trial of ixabepilone and carboplatin with or without bevacizumab in patients with previously untreated advanced non-small-cell lung cancer

(2012) David R. Spigel et al.   LUNG CANCER

Phase I/II study of sagopilone (ZK-EPO) plus carboplatin in women with recurrent platinum-sensitive ovarian cancer

(2011) S McMeekin et al.   BRITISH JOURNAL OF CANCER

Class III β -Tubulin (TUBB3): More than a Biomarker in Solid Tumors?

(2011) M. Mariani et al.   CURRENT MOLECULAR MEDICINE

Differential in vitro sensitivity to patupilone versus paclitaxel in uterine and ovarian carcinosarcoma cell lines is linked to tubulin-beta-III expression

(2011) Luisa Carrara et al.   GYNECOLOGIC ONCOLOGY

Class III β-tubulin and the cytoskeletal gateway for drug resistance in ovarian cancer

(2011) Marta De Donato et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Neoadjuvant chemotherapy in ovarian, primary peritoneal and tubal carcinoma: can imaging results prior to interval debulking predict survival?

(2011) Joseph Menczer et al.   Journal of Gynecologic Oncology

Specific β-Tubulin Isotypes Can Functionally Enhance or Diminish Epothilone B Sensitivity in Non-Small Cell Lung Cancer Cells

(2011) Pei Pei Gan et al.   PLoS One

Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer

(2010) Ignace Vergote et al.   NEW ENGLAND JOURNAL OF MEDICINE

Does Neoadjuvant Chemotherapy Increase Optimal Cytoreduction Rate in Advanced Ovarian Cancer? Meta-Analysis of 21 Studies

(2009) Sokbom Kang et al.   ANNALS OF SURGICAL ONCOLOGY

In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma

(2009) K El-Sahwi et al.   BRITISH JOURNAL OF CANCER

Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials

(2009) Andreas du Bois et al.   CANCER

Phase II Trial of Ixabepilone As Second-Line Treatment in Advanced Endometrial Cancer: Gynecologic Oncology Group Trial 129-P

(2009) Don S. Dizon et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Clinical Trial of Ixabepilone in Patients With Recurrent or Persistent Platinum- and Taxane-Resistant Ovarian or Primary Peritoneal Cancer: A Gynecologic Oncology Group Study

(2009) Koen De Geest et al.   JOURNAL OF CLINICAL ONCOLOGY

Differences in the Expression Profiles of Excision Repair Crosscomplementation Group 1, X-Ray Repair Crosscomplementation Group 1, and βIII-Tubulin Between Primary Non-small Cell Lung Cancer and Metastatic Lymph Nodes and the Significance in Mid-Term Survival

(2009) Chang Hyun Kang et al.   Journal of Thoracic Oncology

The role of βIII tubulin in predicting chemoresistance in non-small cell lung cancer

(2009) Pascal Sève et al.   LUNG CANCER

Hypoxia induces class III beta-tubulin gene expression by HIF-1α binding to its 3' flanking region

(2007) Giuseppina Raspaglio et al.   GENE

The impact of bulky upper abdominal disease cephalad to the greater omentum on surgical outcome for stage IIIC epithelial ovarian, fallopian tube, and primary peritoneal cancer

(2007) Oliver Zivanovic et al.   GYNECOLOGIC ONCOLOGY